Rajkumar  Hirani accused of sexual assault during 'Sanju' shoot

Agencies
January 13, 2019

Mumbai, Jan 13: Filmmaker Rajkumar Hirani has been accused of sexual assault by a woman who worked with him on his 2017 film "Sanju".

Hirani has categorically denied the allegations. His lawyer Anand Desai termed the allegations "false, mischievous, scandalous, motivated and defamatory".

In an article on HuffPost India, the woman, who calls herself as "an assistant", alleged that Hirani sexually abused her more than once between March and September 2018.

She detailed her allegations in an email dated November 3, 2018, to Hirani's longtime collaborator and "Sanju" co-producer Vidhu Vinod Chopra.

The woman said that on April 9, 2018, the director first passed a sexually suggestive remark to her and later sexually assaulted her at his home office.

"I remember forming these words on my lips - 'Sir, This is wrong. Because of this power structure. You being the absolute power and me being a mere assistant, a nobody - I will never be able to express myself to you'," she wrote of the April 9 incident in the email to Chopra, as quoted by HuffPost India.

The woman said that Hirani was a father figure for her.

"My mind, body and heart were grossly violated that night and for the next 6 months," the email read.

Chopra's wife, film critic Anupama, who is a director at Vinod Chopra Films Pvt Ltd, "Sanju" scriptwriter Abhijat Joshi and filmmaker Shelly Chopra, Vidhu Vinod's sister, were also marked on the email.

The complainant later spoke to HuffPost India that she was "intimidated by Hirani", who was her reporting person at the time.

She said she maintained a facade of normalcy regarding Hirani's behaviour as she needed to hold on to her job as her father was suffering from a terminal illness.

"I had no choice but to be polite to him. It was unbearable but the reason I endured it all, until I couldn't, was because I didn't want my job to be taken away from me, and work to be questioned. Ever.

"I was worried that if I left midway, it would be impossible to find another job in this industry if he were to speak badly about my work. Because if Hirani said I wasn't good, everybody would listen. My future would be in jeopardy," she said.

Anupama Chopra had confirmed that the woman had shared an account with her, and that Vinod Chopra Films (VCF) has since set up a committee to address complaints of sexual harassment.

"I have offered my full support and recommended that she take the complaint to a legal body or a neutral party since we cannot be arbitrators or judges on this.

"We also offered to set up an ICC at VCF (which we have set up since then) even though a VCF ICC could not have taken up the case since she was an RHF (Rajkumar Hirani Films) employee at the time. These are two separate companies," she said in an email dated December 5, 2018.

Anupama said the woman told her she needed time to think about how to take things forward.

She added, "I did not want in any way to pressurise her or steer her in any direction. As Vinod and I told her then, she has our full support and we are fully respectful of whatever decision she has taken."

The development comes close on the heels of Hirani's name been dropped from the new poster and trailer of "Ek Ladki Ko Dekha Toh Aisa Laga", directed by Shelly Chopra.

A still from the film's teaser, which released on 27 June, 2018, carried Hirani's name as co-producer.

Vidhu Vinod Chopra has not yet commented.

Hirani's is the latest name to be called out in India's #MeToo storm, which has engulfed many a stalwart such as Nana Patekar, Alok Nath, Vikas Bahl, Sajid Khan and former Union minister MJ Akbar, among others.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 19,2020

President Donald Trump gave a new justification for killing Qassim Suleimani, telling a gathering of Republican donors that the top Iranian general was "saying bad things about our country" before the strike, which led to his decision to authorise his killing. "How much are we going to listen to?" Trump said on Friday, according to remarks from a fundraiser obtained by CNN.

With his typical dramatic flourish, Trump recounted the scene as he monitored the strikes from the White House Situation Room when Suleimani was killed. The president spoke in a ballroom at his Mar-a-Lago club in Palm Beach, Florida, at a Republican event that raised $10 million for Trump's 2020 campaign.

The January 3 killing of Suleimani prompted Iran to retaliate with missile strikes against US forces in Iraq days later and almost triggered a broad war between the two countries. "They're together sir," Trump said military officials told him. "Sir, they have two minutes and 11 seconds. No emotion. Two minutes and 11 seconds to live, sir. They're in the car, they're in an armoured vehicle. Sir, they have approximately one minute to live, sir. Thirty seconds. Ten, 9, 8 ...'"

"Then all of a sudden, boom," he said. "They're gone, sir. Cutting off, I said, where is this guy?" Trump continued. "That was the last I heard from him". It was the most detailed account that Trump has given of the drone strike, which has drawn criticism from some US lawmakers because neither the president nor his advisers have provided public information to back up their statements that Suleimani presented an "imminent" threat to US.

Trump's comments came a day after he warned Iran's supreme leader Ayatollah Ali Khamenei to be "very careful with his words". According to Trump, Khamenei's speech on Friday, in which he attacked the "vicious" US and described UK, France and Germany as "America's lackeys", was a mistake.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 5,2020

Nalgonda,  Jul 5: Bollywood filmmaker Ram Gopal Varma has been booked in connection with his upcoming film 'Murder' which is based on Pranay Kumar's murder in Nalgonda district.

Ram Gopal Varma was booked following Nalgonda court's directive on a petition filed by father of a man who was killed in an alleged honour killing incident in Miryalaguda in 2018.

"We have booked filmmaker Ram Gopal Varma following a court order for his upcoming movie 'Murder', which is based on sensational caste-based Pranay Kumar's murder that occurred in Miryalguda, Nalgonda District in September 2018, " Police said.

On June 21, the filmmaker has released the poster of 'Murder', based on a true story.
Police said, "Pranay's father Balaswamy has filed a petition in Nalgonda Court stating that the film will affect the on-going trial of Pranay's murder case and the film should be stalled."

"We've registered a case under relevant section of SC/ST (Prevention of Atrocities) Amendment Act and taken up investigation."

"The court has ordered Nalgonda police to register a case against the film director Ram Gopal Varma and the producer," added the police.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.